Evidence map›Paper›PMID 30385049›Full record

ArticleEuropean urology2019

Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

Mieke Van Hemelrijck, Xi Ji, Jozien Helleman, Monique J Roobol, Wim van der Linden, Daan Nieboer, Chris H Bangma, Mark Frydenberg, Antti Rannikko, Lui S Lee and 4 more

Registry-linked trialOpen access · greenAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07790003 (Dietary Fibre Supplementation to Delay Disease Progression in Early Prostate Cancer), which is not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07790003 completednot on this mapstarted 2024, after this paper: background citation

Dietary Fibre Supplementation to Delay Disease Progression in Early Prostate Cancer

TypeobservationalSponsorUniversity of AberdeenRan2024 to 2024Enrolled10ConditionsProstate Cancer, Prostatic Neoplasm, Dietary Fibre Modification, Active SurveillanceArmsQualitative semi-structured interviews, Focus group
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Surveillance after Focal Therapy - a Comprehensive Review.Prostate cancer and prostatic diseases · 2025
    Review
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 6 countries.

Mieke Van HemelrijckTranslational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. Electronic address: Mieke.vanhemelrijck@kcl.ac.uk.
Xi JiDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
Jozien HellemanDepartment of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Monique J RoobolDepartment of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Wim van der LindenDepartment of Professional Health Solutions & Services, Philips Research, Eindhoven, The Netherlands.
Daan NieboerDepartment of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Chris H BangmaDepartment of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Mark FrydenbergDepartment of Surgery, Monash University, Melbourne, Australia; Department of Urology, Monash Health, Melbourne, Australia.
Antti RannikkoHelsinki University and Helsinki University Hospital, Helsinki, Finland.
Lui S LeeDepartment of Urology, Singapore General Hospital, Singapore.
Vincent J GnanapragasamAcademic Urology Group, Department of Surgery and Oncology, University of Cambridge, Cambridge, UK.
Mike W KattanDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium
Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium
Erasmus MC · NLCleveland Clinic · USUniversity of Cambridge · GBHelsinki University Hospital · FIKing's College London · GBMonash University · AUPhilips (Netherlands) · NLSingapore General Hospital · SGMonash Health · AU

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundCareful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa).

objectiveUsing Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation. DESIGN, SETTING, AND

participantsWe compared data from 10296 men on AS from 21 centres across 12 countries. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation. RESULTS AND LIMITATIONS: During 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for <5yr, and 149 were lost to follow-up. Cumulative incidence of progression was 27.5% (95% CI: 26.4-28.6%) at 5yr and 38.2% (95% CI: 36.7-39.9%) at 10yr. A limitation is that not all centres were included due to limited information on the reason for discontinuation and limited follow-up.

conclusionsOur descriptive analyses of current AS practices worldwide showed that 43.6% of men drop out of AS during 5-yr follow-up, mainly due to signs of disease progression. Improvements in selection tools for AS are thus needed to correctly allocate men with PCa to AS, which will also reduce discontinuation due to conversion to active treatment without evidence of disease progression. PATIENT SUMMARY: Our assessment of a worldwide database of men with prostate cancer (PCa) on active surveillance (AS) shows that 43.6% drop out of AS within 5yr, mainly due to signs of disease progression. Better tools are needed to select and monitor men with PCa as part of AS.

Indexed as

Early Detection of CancerPatient DropoutsWatchful WaitingAgedAsiaAustraliaBiopsyCause of DeathClinical Decision-MakingDatabases, FactualDisease ProgressionEuropeHumansKallikreinsMaleMiddle AgedKallikreinsKLK3 protein, humanProstate-Specific AntigenActive surveillanceDiscontinuationProstate cancerWorldwide

Identifiers

PMID30385049
PMCPMC8542419
OpenAlexW2898746949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.